The Company’s ImmunoBody® platform is designed to induce potent cytotoxic CD8 T cell responses against multiple epitopes via a unique dual-mechanism of action to stimulate a broad anti-tumour effect. They are DNA vaccines that encode a protein in the form of a modified antibody, which is engineered to express epitopes from a cancer antigen whilst retaining the ability to target activated antigen presenting cells in vivo. The potent immune responses induced by ImmunoBody® vaccines have been shown to result in long term survival in melanoma patients treated with Scancell’s first ImmunoBody® vaccine, SCIB1.
Scancell is also using its proven cancer vaccine concept to design a vaccine against SARS-CoV-2, the virus that causes COVID-19. We have designed a DNA vaccine to stimulate high avidity T cells and give durable responses, ultimately leading to better protection. In addition to the receptor binding domain of the spike protein, Scancell’s vaccine also targets the nucleoprotein, which is highly conserved amongst coronaviruses. This vaccine may therefore also confer protection against new emerging coronaviruses that may evolve in the future.